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Abstract
An inherited polyneuropathy (PN) observed in Leonberger dogs has clinical similarities to a genetically heterogeneous group of
peripheral neuropathies termed Charcot-Marie-Tooth (CMT) disease in humans. The Leonberger disorder is a severe, juvenile-
onset, chronic, progressive, and mixed PN, characterized by exercise intolerance, gait abnormalities and muscle atrophy of the
pelvic limbs, as well as inspiratory stridor and dyspnea. We mapped a PN locus in Leonbergers to a 250 kb region on canine
chromosome 16 (Praw=1.16610
210, Pgenome, corrected = 0.006) utilizing a high-density SNP array. Within this interval is the
ARHGEF10 gene, a member of the rho family of GTPases known to be involved in neuronal growth and axonal migration, and
implicated in human hypomyelination. ARHGEF10 sequencing identified a 10 bp deletion in affected dogs that removes four
nucleotides from the 39-end of exon 17 and six nucleotides from the 59-end of intron 17 (c.1955_1958+6delCACGGTGAGC). This
eliminates the 39-splice junction of exon 17, creates an alternate splice site immediately downstream in which the processed
mRNA contains a frame shift, and generates a premature stop codon predicted to truncate approximately 50% of the protein.
Homozygosity for the deletion was highly associated with the severe juvenile-onset PN phenotype in both Leonberger and
Saint Bernard dogs. The overall clinical picture of PN in these breeds, and the effects of sex and heterozygosity of the ARHGEF10
deletion, are less clear due to the likely presence of other forms of PN with variable ages of onset and severity of clinical signs.
This is the first documented severe polyneuropathy associated with a mutation in ARHGEF10 in any species.
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Introduction
Charcot-Marie-Tooth (CMT) disease is a heterogeneous mix of
hereditary motor and sensory neuropathies in humans, for which
mutations in more than thirty genes have already been described
(Inherited Peripheral Neuropathies Mutation Database). CMT
disease is the most common inherited disorder of the peripheral
nervous system in humans, affecting an estimated 8 to 41 per 100,000
globally [1]. Classification of CMT cases has historically been based
on clinical and electrophysiological findings, histopathology, and the
pattern of inheritance, but is now increasingly based on the
underlying genetic defect [2]. Unfortunately, the molecular basis of
many rare CMT forms remains unsolved. With no curative therapy
for human patients with CMT, suitable animal models for
development of therapeutic agents and other treatment modalities
are highly desirable [3]. Many of the described muscle and peripheral
nerve diseases in dogs are suspected to be inherited [4], and it has
been suggested that many canine inherited neuropathies strongly
resemble forms of CMT disease [5,6]. The recent identification of
mutations in the NDRG1 (ENSCAFG00000001141) gene in
Greyhounds [7] and Alaskan Malamutes [8] with early-onset
polyneuropathy supports this hypothesis.
An inherited polyneuropathy (PN) in Leonberger dogs [9] also
demonstrates striking similarities to an intermediate form of CMT
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disease. Leonbergers are a large-bodied breed, reaching adult
weights of 45 to 77 kilograms. PN in this breed is characterized by
generalized weakness, hypotonia, and muscle atrophy secondary
to denervation, particularly of the pelvic limbs [9]. Affected dogs
frequently present with a high-stepping pelvic limb gait (pseudo-
hypermetria of the hock) [6], decreased or absent tendon reflexes,
and changes associated with degeneration of the recurrent
laryngeal nerve, including inspiratory stridor resulting from
laryngeal paralysis. The age-of-onset of clinical signs can vary
from ,1 year up to 11 years of age; however, the juvenile-onset
patients typically have a more severe and rapidly progressing
course of disease. Peroneal nerve biopsies show decreased
myelinated fiber density resulting from axonal degeneration and
endoneurial fibrosis indicative of chronic nerve fiber loss. Cranial
tibial muscle biopsies demonstrate neurogenic atrophy and fatty
replacement of muscle fibers indicative of chronic denervation [9].
There is no effective direct therapy for these pathologies, although
some relief can be achieved for laryngeal problems by arytenoid
cartilage lateralization (called a ‘‘tieback’’ surgery).
A predominance of affected males led to the initial suspicion
that PN in Leonbergers was an X-linked disorder, although
autosomal recessive inheritance could not be ruled out [9]. A more
recent multi-generation pedigree analysis also concluded an X-
linked mode of inheritance, with possible influence by other loci
that impact age-of-onset and severity of signs [10]. Nevertheless,
numerous affected Leonberger females with juvenile-onset PN,
coupled with increasing recognition of a wide range in ages of
onset and clinical severity of PN, indicate that the underlying
genetic mechanisms responsible for PN in this breed remain to be
defined. We therefore performed a genome-wide association study
(GWAS) with high-density canine SNP arrays in cohorts of
Leonberger PN cases and controls, with the aim of identifying
genetic defect(s) that contribute to PN. A loss-of-function
ARHGEF10 (ENSCAFG00000013667) deletion was identified
which, although not explanatory for all Leonberger polyneurop-
athy, is highly-associated with a juvenile-onset form of the disease.
Results
Genome-Wide Association Mapping
A cohort of 52 PN cases and 41 controls was genotyped on
Illumina CanineHD BeadChips. After pruning for low genotyping
rate, low minor allele frequencies, and failure to meet Hardy-
Weinberg equilibrium, 101,284 SNPs remained for the association
analysis, which was initially conducted in PLINK [11]. A highly
significant CFA16 locus was identified, with the most significant
SNP (BICF2G630820235, at bp position 57,375,008, using
CanFam2 positions) achieving a raw P-value of 1.16610210,
and a genome-wide P-value of 1.0061024 after 10,000 permuta-
tions (Figure 1A). A potential locus was also observed on CFA7,
with the best associated SNP (BICF2P881479, at bp position
25,815,288) achieving a raw P-value of 4.6461027, and a genome-
wide P-value of 0.015 after 10,000 permutations. A genomic
inflation factor (lambda) of 1.38 indicated the presence of
population stratification and possible cryptic relatedness. This
was unsurprising, given that Leonbergers are a breed globally
small in numbers, and due to this demographic history, the dogs
selected for genotyping on the SNP arrays were unavoidably
closely related. We therefore performed an association analysis
using the mixed model function implemented in GenABEL [12]
that resulted in lambda dropping to 1.004. The same CFA16 and
CFA7 SNPs achieved the lowest P-values: 1.9061027 and
5.7961025 for CFA16 and CFA7, respectively (Figure 1B).
However, with 10,000 permutations of the mixed model test, the
CFA16 locus remained significant (Pgenome, corrected = 0.006), while
the CFA7 SNP achieved a p-value of only 0.68 (Pgenome, corrected).
The quantile-quantile plot of observed versus expected P-values of
this mixed model permuted analysis also supports the effectiveness
of the correction for population structure and the significance of
the CFA16 locus (Figure 1C).
Identification and Characterization of an ARHGEF10
Mutation
Shared homozygosity in many PN-affected dogs, and absence of
homozygosity in controls, identified a 250 kb minimum haplotype
at the CFA16 locus. This interval contains only two genes: rho
guanine nucleotide exchange factor 10 (ARHGEF10) and
myomesin 2 (MYOM2, ENSCAFG00000024660) (Figure 2).
ARHGEF10 was pursued as a positional and functional candidate
gene due to its previous implication in peripheral nerve
development and human peripheral hypomyelination [13].
Similar to humans, the canine ARHGEF10 gene has 29 coding
exons, with two alternative transcripts that either include or
exclude exon 9, encoding a longer and shorter form of the protein.
We first sequenced all coding exons, along with flanking intron
boundaries, in four juvenile-onset severely-affected dogs, and four
control dogs. This analysis revealed 98 sequence variants in
comparison to the canine reference genome sequence (Table S1).
Two SNPs predicted an amino acid change that was observed in
both cases and controls, and the other exonic variants were
synonymous. Two of the four cases used for sequencing were
homozygous for the disease-associated CFA16 haplotype, and
both of these dogs possessed a private 10 bp deletion
(c.1955_1958+6delCACGGTGAGC). This deletion removes four
nucleotides from the 39-end of exon 17 (nts 1955 to 1958) and six
nucleotides from the 59-end of intron 17 (nts 1958+1 to +6)
(Figure 3A). A dog that is heterozygous for the CFA16 haplotype
(D/N) was subsequently sequenced and the results were in accord
with heterozygosity for the 10 bp deletion (Figure 3A).
The effect of the deletion on the ARHGEF10 transcript was
investigated with cDNA prepared from the nervous tissue of an
Author Summary
Leonberger dogs are a breed originally produced by
crossing large-bodied dogs, including Saint Bernards and
Newfoundlands. A peripheral neuropathy has been de-
scribed in Leonbergers that is similar to a group of
inherited polyneuropathies known as Charcot-Marie-Tooth
disease in humans. We collected a cohort of well-
characterized Leonberger polyneuropathy cases and con-
trols, conducted a genome-wide association study, and
ultimately identified a highly associated and likely causa-
tive mutation in the AHGEF10 gene. This sequence variant
is a 10-bp deletion encompassing a splice site, which
forces use of a downstream splice site to create a
processed mRNA with a premature stop codon, and
represents a loss-of-function mutation. The identical
mutation was also found in several polyneuropathy-
affected Saint Bernards. When homozygous, this deletion
results in the onset of clinical signs before four years of
age. ARHGEF10 has not previously been associated with
severe CMT, but comes from a family of genes shown to be
involved in neuron morphology. This first-documented
severe polyneuropathy associated with an ARHGEF10
mutation in any species provides an opportunity to gain
further insights into the pathobiology of diseases associ-
ated with this gene. The ARHGEF10 mutation does not,
however, by itself account for all cases of polyneuropathy
in Leonbergers or Saint Bernards.
An ARHGEF10 Mutation in Dogs with Polyneuropathy
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Figure 1. Genome-wide association mapping of Leonberger PN. (A) Manhattan plot of GWAS for PN with 93 (52 cases, 41 controls)
Leonbergers. X-axis = chromosome, Y-axis = negative decadic logarithms of permutation-corrected P-values. (B) Manhattan plot of GWAS for PN with
93 Leonbergers. X-axis = chromosome, Y-axis = negative decadic logarithms of permutation-corrected P-values, after correction for population
stratification and cryptic relatedness using a mixed model approach and genomic control. (C) The quantile-quantile (QQ) plot corresponding to (B).
doi:10.1371/journal.pgen.1004635.g001
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early-onset Leonberger PN case homozygous for the CFA16
haplotype (D/D), a CFA16 haplotype heterozygote (D/N) Leon-
berger with no polyneuropathy, and one control dog (N/N).
Sequencing of an RT-PCR product containing the exon 17- exon
18 junction showed that mRNA produced in the PN-affected
Leonberger, but not the control, lacked 4 bp from the 39-end of
exon 17, while containing the entirety of exon 18 (Figure 3B). This
is consistent with the utilization of an alternate GT splice site
immediately downstream from the normal splice site, which is
deleted. The resultant mutant transcript contains a frame-shift
which predicts a truncation of 50.5% of the amino acid sequence
from the long form of the protein (52% of the short form). This
predicts deletion of a WD40-like domain and two transmembrane
segments. We detected only wild type sequence from the cDNA of
the heterozygote, most likely due to poor amplification of the
mutant sequence relative to wild type that would result from
nonsense-mediated decay.
All 93 Leonbergers from the original GWAS cohort were then
genotyped for the ARHGEF10 deletion (Table 1). Eighteen of the
52 (35%) cases were homozygous for the deletion (D/D), 14 (27%)
were heterozygous (D/N), and 20 (38%) were homozygous normal
(N/N). The 18 D/D dogs represented both sexes and developed
clinical signs at or before the age of three years; most did so before
the age of two. Three D/N dogs and eight N/N dogs also
developed PN signs at #3 years of age. None of the original 41
controls were D/D, four out of 41 (10%) were heterozygous D/N,
and 37 (90%) were N/N.
Effects of Genotype, Sex, and Age on the PN Phenotype
We next genotyped a larger and independent population of case
(n = 154) and control (n = 160) Leonbergers (‘‘Validation Group’’)
(Table 1), where the association of the ARHGEF10 mutation with
PN was confirmed (genotypic and allelic P-values of 9.5761026
and 5.9861027, respectively). When combined, the GWAS and
validation populations comprised 206 cases and 201 controls,
which increased the significance of the genotypic and allelic
frequency differences (P-values of 5.01610211 and 2.75610215,
respectively).
Overall, 44.4% (36/81) of young age-of-onset (#3 years) cases
had the D/D ARHGEF10 genotype (Table 1, Figure 4). Forty-one
of the 81 early onset cases had undergone a nerve biopsy that
showed pathological changes consistent with PN, and 21 of these
(51.2%) were homozygous for the ARHGEF10 deletion. In total,
90 of the 206 cases had undergone peripheral nerve biopsy to
Figure 2. SNP haplotypes and genes from the GWAS identified CFA16 region associated with Leonberger PN. A representative sample
of the observed CFA16 haplotypes is demonstrated using eleven Leonbergers, with both haplotypes shown for each dog as green or yellow bars. LEO
1-4 and LEO 9 - 11 are cases (indicated in red), while LEO 5-8 are controls (indicated in blue). The most significantly associated SNP
(BICF2G630820235) is highlighted in orange. Green bars represent the most significantly associated haplotype, which, in some cases extended the
entire 1.5 Mb region. However, a minimum associated haplotype of approximately 250 kb (enclosed in the dark outlined box) was observed. An
alternate haplotype, demonstrated by the yellow bars, was present in many of the controls and some of the cases. Some PN cases (LEO 9-11) are
either heterozygous or devoid of the ‘‘green’’ case-associated haplotype and a phenotypically normal dog (LEO 8) is heterozygous for the associated
haplotype. CFA16 (Mb, CanFam2) ENSEMBL-annotated genes in the region are shown at the bottom of the figure.
doi:10.1371/journal.pgen.1004635.g002
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confirm pathological changes consistent with PN, with 21 of them
(23.3%) being homozygous for the ARHGEF10 deletion.
In the combined population, 30 D/D cases are male and seven
D/D cases are female. Affected males outnumber affected females
in nearly every category of genotype and age-of-onset (Table 1).
When the data is normalized to the number of samples from each
sex, 65% of the submitted males were affected and 34% of the
submitted females were affected.
The effects of heterozygosity for the ARHGEF10 deletion were
also ascertained in the combined population. Sixty percent (45 of
75) of all D/N dogs were PN cases and 40% (30 of 75) were
controls (Table 1). D/N dogs accounted for 21.8% of all PN cases
(45 of 206) and 14.9% of all controls (30 of 201), and represent
only a slightly significant difference in ‘‘D’’ allele frequency
between cases and controls (P-value = 0.009). The average age-of-
onset of clinical signs for cases in the combined population was
1.73, 6.14 and 5.59 years for D/D, D/N and N/N dogs,
respectively. Thus heterozygous or homozygous normal PN cases
developed clinical signs at a similar later stage in life (Figure 4).
Based on our assessment of medical records, PN cases that were
heterozygous for the ARHGEF10 deletion were less likely to
develop severe disease than were D/D dogs.
A global group of 4,074 Leonbergers, primarily originating from
North America and Europe, have been submitted to our
laboratories since the discovery of the ARHGEF10 mutation. In
this non-random sample, 1.3% of these dogs were homozygous for
the ARHGEF10 mutation, 15.4% were heterozygous, and the
‘‘D’’ allele frequency was 9.0%. There was no significant
difference between numbers of D/D males (34/54) and D/D
females (20/54) (P-value = 0.077).
ARHGEF10 Deletion in Saint Bernards and Other Breeds
The Leonberger breed resulted from crossing several breeds,
including the Saint Bernard, Newfoundland, and Great Pyrenees,
making it possible that the ARHGEF10 mutant allele could be
present in these breeds as well. To date we have identified the
identical deletion mutation in a homozygous state in four (2 males,
2 females) Saint Bernard dogs with early-onset PN. Of these four
dogs, three were confirmed as PN-affected with a nerve biopsy,
and all four showed similar clinical signs to those seen in D/D
Leonbergers, including laryngeal paralysis, pelvic limb deficits and
flaccid paraparesis, and severe neurogenic muscle atrophy. All four
were deceased by the age of two years as a result of their disease. A
random sample of 383 Saint Bernards found 1.8% of them to be
heterozygous and 98.2% of them to be homozygous normal. (Note
that the four D/D dogs are not included in the random sample, as
they were acquired via diagnostic sample submission after showing
clinical signs).
Other related breeds, and breeds with clinical PN, have also
been genotyped for the ARHGEF10 deletion and all were N/N
(Table S2). This includes Newfoundlands (n = 359, three with PN
diagnosed by nerve biopsies), Greater Swiss Mountain Dogs
(n = 48), Bernese Mountain Dogs (n = 2, both with PN diagnosed
by nerve biopsies), Great Pyrenees (n = 7, two with PN diagnosed
by nerve biopsies), Great Danes (n = 4, all with PN diagnosed by
nerve biopsies), and a single Golden Retriever (also with PN
diagnosed by nerve biopsy).
Follow-up of CFA7
We genotyped one of the most significantly associated CFA7
SNPs (TIGRP2P93473_rs9189862) from the initial GWAS in a
Figure 3. ARHGEF10 mutation analysis. (A) Genomic DNA. Electropherograms of the ARHGEF10 c.1955_1958+6delCACGGTGAGC mutation.
Representative sequence traces of PCR products amplified from genomic DNA of 3 dogs with the different genotypes are shown. (B) Transcript.
Electropherograms of RT-PCR using primers in exon 17 and 19. Representative sequence traces of RT-PCR products amplified from cDNA of 3 dogs
with the different genotypes are shown. Note the underrepresentation of the mutant transcript in the heterozygous dog, which is probably due to
nonsense mediated decay (NMD). Both the normal and the new splice site created by the deletion are underlined (Panel A); the cryptic splice site in
the deletion allele creates a cDNA missing only four base pairs, which creates a frame shift and predicts a premature stop codon within seven amino
acid residues (Panel B).
doi:10.1371/journal.pgen.1004635.g003
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large Leonberger population of 193 cases and 174 controls
(Table 1). This resulted in a large decrease of both genotypic and
allelic significance for this SNP, indicating that the weaker initial
association did not maintain significance.
Discussion
There are only two early-onset peripheral neuropathies with a
known genetic basis in dogs; both being autosomal recessive
conditions due to mutations in the NDRG1 gene [7,8]. PN in the
Leonberger was initially considered to be a single, possibly X-
linked, disorder [9,10]. However, we now understand that
Leonberger dogs affected with PN can display a broad range of
age-of-onset, so it is reasonable to conclude that PN in this breed,
like CMT disease in humans, may not be a single disease with one
underlying genetic mutation. Nevertheless, we were able to utilize
a GWAS strategy to identify a highly significantly associated locus
on CFA16. We found a biologically noteworthy positional
candidate gene, ARHGEF10, that harbored a 10 base deletion
affecting the coding sequence. We further confirmed the
association of this mutation with juvenile-onset PN in a large,
independent validation group of Leonbergers, characterized the
effects of genotype, age and sex on the mutation’s association with
PN, and detected it in cases of early-onset PN in Saint Bernard
dogs. ARHGEF10 belongs to a large family of Rho guanine
nucleotide exchange factors (GEFs), which are activators of Rho-
GTPases, molecular switches that participate in the regulation of a
large number of signal transduction pathways, some of which
influence cell polarity, specifically neuron morphology, including
axon, dendrite, and spine growth, and axon guidance [14].
RhoGTPases are also specifically involved in directing the
migration of Schwann cell precursors along outgrowing axons
[15]. As ARHGEF10 is expressed in multiple tissues, with
relatively higher expression in the spinal cord and dorsal root
ganglion [13] (and USCS Genome Browser), we hypothesize that
the loss of ARHGEF10 leads to the loss of proper signaling for
axon ensheathment and myelination in Leonberger PN.
Autosomal recessive mutations in the rho GTPase GEF frabin/
FGD4 gene have been previously implicated in demyelination of
peripheral nerves in cases of CMT type 4H [16,17], and an
autosomal dominant point mutation predicting a missense
mutation in exon 3 of ARHGEF10 has been identified in a
human family experiencing non-clinical slowed nerve-conduction
velocities [13]. A nerve biopsy of the human proband in this family
revealed numerous thinly myelinated axons, without any gross
signs of demyelination or axonal degeneration and regeneration,
and none of the affected family members in the study experienced
progression of symptoms. Subsequent work examining this human
ARHGEF10 mutation concluded that the relatively mild pheno-
type is due to activation of GEF activity [18]. Conversely,
Leonberger PN cases in the present study have decreased nerve
fiber density, and chronic nerve fiber loss, resulting from axonal
degeneration with progressive clinical signs of weakness and
muscle atrophy. Given that the ARHGEF10 deletion in
Leonbergers truncates approximately 50% of the protein, and
the deleted portions contained the WD40-like domain and both
transmembrane segments [19], it is reasonable to suggest that the
severe and progressive clinical and pathological phenotype
observed in Leonbergers homozygous for the mutation is due to
the loss-of-function of this GEF’s activity. This is the first report of
an ARHGEF10 mutation in any species resulting in a severe
juvenile-onset PN.
Figure 4. Age-of-onset based on ARHGEF10 genotype. Age-of-onset of clinical signs for all well-phenotyped cases (where age-of-onset was
reported) is shown for all cases from the original GWAS and the independent, validation group, by ARHGEF10 genotype. Not all 206 dogs are shown
due to the fact that, while we sometimes knew the dog had clinical signs by a certain age, the exact onset of those signs before that age was
unknown.
doi:10.1371/journal.pgen.1004635.g004
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Our data suggests that LPN1 (PN due solely to the ARHGEF10
mutation) is most likely inherited in an autosomal recessive
manner and explains approximately one-fifth of all PN cases in
Leonbergers. There is a slight excess of D/N heterozygote cases
(compared to controls) (Table 1); this could be due to: 1)
interaction with another locus, 2) the possibility that the deletion
is actually semidominant, in which case, all homozygous D/D
dogs become affected early in life, while heterozygous D/N dogs
have an elevated risk of developing less severe disease later in life
compared to truly normal N/N dogs, 3) that there are one or
several rare additional undetected ARHGEF10 variants, or 4)
sampling bias in the case population. A semidominant mode of
inheritance seems doubtful, due to the fact that we have observed
many D/N dogs without clinical signs of PN. Although we favor
the recessive model, we cannot, as yet, entirely rule out any of
these hypotheses. It has been recognized in several studies [20–24]
that laryngeal paralysis is a strong indicator of the presence of an
underlying ‘silent’ polyneuropathy that may later progress; this is
likely the scenario with many of our later-onset Leonberger cases,
whose clinical presentation is different than dogs with juvenile-
onset. Therefore, we suggest that additional cases of PN could be
due to other unidentified PN-causing mutation(s), and may be
influenced by age, sex, environmental or other genetic factors.
A sex bias in submitted PN cases toward males is evident, as
70% of all cases were male, and 65% of all males in the study were
affected, as compared to 37% of all females. Nevertheless, male
and female homozygotes for the ARHGEF10 deletion exhibit the
same classic clinical signs of peripheral PN, and in the global
population of .4,000 genotyped Leonbergers there was no
statistical difference in sex distribution of D/D cases. The
identification of an autosomal PN-causing ARHGEF10 mutation,
and no indication of association of PN to SNPs on the X
chromosome in our GWAS, contradicts the previously assumed X-
linked inheritance [9,10]. Hultin Jaderlund et al. argue from a
limited pedigree analysis that inherited PN in Leonbergers is likely
to be a single disease with an X-linked mode of inheritance, which
is genetically different in Europe and the Americas, and descended
from a Leonberger female, born in 1943. However, our study,
using to the extent possible the gold standard of peripheral nerve
biopsy to confirm a diagnosis of PN, combined with mutation
identification and analysis on a large, world-wide sample cohort,
indicates that: 1) Leonberger PN represents at least two, if not
more, distinct inherited diseases, 2) the first identified PN mutation
is autosomal, and 3) it is found worldwide.
A possible explanation for the higher number of males affected is
that males develop more severe clinical signs at an earlier age
because they are typically larger than females, with correspondingly
longer peripheral nerves (those typically more susceptible and
affected first in peripheral neuropathies [25]). An alternative
explanation involves the effects of neuroactive endogenous steroids,
such as progesterone, testosterone, and their derivatives on the
peripheral nervous system. These steroids originating from both
peripheral glands and the nervous system [26] influence neurode-
generative processes as well as signaling pathways involved in
neuronal cell death [27]. Neuroactive steroid levels in a rat model of
CMT type 1A are sexually dimorphic [28], and a recent study of rat
peripheral nerve cell cultures demonstrated a sex difference in the
promotion of Schwann cell proliferation by neuroactive steroids
[29]. Finally, it has been suggested that sex differences in DNA
methylation patterns may be exerted on the developing nervous
system by steroid hormones [26]. It is entirely possible, then, that
the overall sex-difference in Leonberger peripheral nerve pathology
is a result of sex-specific presence and ability to respond to
neuroactive steroids and/or epigenetic changes they introduce.
The initially detected suggestive association on CFA7 was a
possibility for a second inherited PN locus segregating in the
Leonberger breed; however, it was not confirmed in a larger
population. Although we might have missed identifying a non-
coding regulatory mutation within the associated haplotype, it
seems more likely that by random chance the controls selected for
the GWAS population had fewer copies of a CFA7 haplotype that
is actually quite common in the breed, which in turn misrepre-
sented the allele frequencies and led to the appearance of
significant association. While we cannot rule out that this CFA7
locus is involved with a subset of PN cases in Leonbergers, it is
likely that a far more powerfully-designed GWAS will be necessary
to identify additional PN loci in this breed.
Besides apparent cases of PN caused by different genetic
mutations, it is possible that some of the non-LPN1 ‘‘cases’’ in our
sample collection are not truly PN and might represent
misdiagnosed phenocopies. A gold standard for diagnosing PN
would include measurement of motor and sensory nerve
conduction velocities (for demyelination), amplitude of the
compound muscle action potential (for axonal loss), histopathology
of peripheral nerve biopsies and an examination conducted by a
board-certified veterinary neurologist. However, since many dogs
had not undergone sufficient diagnostic testing, we were unable to
use these stringent criteria. Diseases such as hip dysplasia, a torn
cruciate ligament, or undiagnosed osteosarcoma, for example, can
induce gait abnormalities that mimic those seen in PN. Without a
complete assessment, owners, and possibly veterinarians, can easily
mistake these diseases, at least in the early stages, with PN. PN
phenocopies can also result from primary hypothyroidism, which
has been associated with peripheral neuropathy in dogs and can
create very similar changes to the nerve appearance on biopsy
[30]. Hypothyroidism typically affects middle to older-aged dogs,
and especially medium to large-sized dogs [31,32]. Therefore an
older-onset hypothyroid dog could be mistaken for an older-onset
PN case. Lastly, a presumptively inherited leukoencephalomyelo-
pathy (LEMP) has been reported in Leonberger dogs [33]. While
LEMP is a disease of the central nervous system and no lesions are
observed in the peripheral nerves, clinical signs such as ataxia and
hypermetria are neurologic in origin, and could be mistaken as
inherited peripheral PN. Despite these phenotyping challenges,
strict case definitions emphasizing the diagnosis of PN from axonal
degeneration and chronic nerve fiber loss observed in a peroneal
nerve biopsy allowed us to assemble a strong case population for
the initial GWAS.
The Leonberger breed was created in the mid-1800s by a citizen
of Leonberg, Germany, who ostensibly crossed a Landseer
Newfoundland female with a St. Bernard male. Other breeds, such
as the Pyrenean Mountain dog were likely also introduced [6]. The
Leonberger breed experienced severe bottlenecks during and after
both World Wars, and it is difficult to ascertain when Saint Bernards
ceased to be interbred with Leonbergers. Clinically and histopath-
ologically confirmed PN, similar to that of the Leonberger dogs,
occurs in the Saint Bernard, Newfoundland, and Great Pyrenees
(Shelton, unpublished observation), but of these three, to date the
ARHGEF10 deletion has only been identified in the Saint Bernard.
Though it is possible that the ARHGEF10 deletion mutation pre-
dates the formation of the Leonberger breed, and was introduced via
the Saint Bernard, it is also possible that the mutation is newer, and
was introduced through more recent cross-breeding. We believe it is
less likely that the mutation arose in the Leonberger breed and was
subsequently introduced to Saint Bernards, given the Saint Bernard’s
longer pedigreed breed establishment. The low sample numbers
tested to date in other breeds does not yet effectively rule-out the
presence of this deletion in any other breed of dog.
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In conclusion, we have identified a 10 bp deletion in the canine
ARHGEF10 gene as the most likely causative mutation for a
juvenile form of PN, now termed LPN1. This mutation explains
20% of all PN-affected Leonbergers and occurs rarely in PN-
affected Saint Bernards. Dog breeders can now select against the
defective ARHGEF10 allele by genotyping breeding animals and
using targeted mating to achieve a significant reduction of PN
incidence; specific breeding recommendations and test result
interpretations from our laboratories are included with this
manuscript as Supporting Information S1. This work suggests a
critical function of ARHGEF10 in normal development and/or
maintenance of peripheral nerves and in so doing we have also
defined an excellent animal model for human CMT.
Materials and Methods
Sample Collection and Ethics Statement
This study was performed using protocols approved by the
Institutional Animal Care and Use Committees (IACUC) of the
University of Minnesota (UM), the University of Bern (UB), and
the University of California San Diego (UCSD). Written consent
was obtained from all dogs’ owners. Leonberger samples were
obtained primarily via elective owner submission or collected at
breed club shows. Medical records, pedigrees, and a blood sample
or cheek swab for DNA extraction were requested from each
Leonberger dog submitted to the UM and UB. Following
identification of the ARHGEF10 mutation, samples of many
more Leonberger dogs were submitted for genotyping. Many of
these dogs do not have complete medical information and were
used only for a population study. Other dogs represented breeds
closely related to the Leonberger (including the Saint Bernard), or
had developed signs of clinical polyneuropathy and/or had a
nerve biopsy showing pathological changes consistent with PN.
Samples submitted to UCSD additionally included nerve and/or
muscle biopsies for diagnostic purposes. A frozen Leonberger
nerve tissue sample from a PN case, shipped originally to UCSD
for diagnostic biopsy purposes, as well as frozen spinal cord tissue
from a Leonberger and frozen brain tissue of a Cavalier King
Charles Spaniel, both unaffected with polyneuropathy and
obtained for purposes of other studies, were used for RNA
isolation and cDNA sequencing. Additional DNA samples used to
examine frequency of the ARHGEF10 deletion in breed
populations (Newfoundlands, Saint Bernards, and Greater Swiss
Mountain Dogs) were collected for other studies and shared by
collaborators (see acknowledgement section).
Case and Control Definitions for 93 Leonberger Dogs
Utilized in the GWAS
The clinical characterization of LPN, including morphometric,
electrophysiological, biopsy and examination findings, has been
described elsewhere [9]. As sample acquisition continued after
publication of the original study, it became clear that a large
spectrum of clinical signs and substantial variety in the available
diagnostic information exists among cases. Therefore, the follow-
ing criteria were established in order to select the best possible
cases and controls for SNP array genotyping:
Cases (n= 52). The dog’s age of onset of clinical signs was
known. A peripheral nerve biopsy, processed and examined in the
Comparative Neuromuscular Laboratory of the author (GDS) or
another veterinary neurohistopathologist using proper plastic
embedding techniques, was positive for the typical Leonberger
polyneuropathy. Clinical signs reported by the owner and/or
veterinarian must have included at least one gait abnormality and
at least one laryngeal abnormality. Accepted gait abnormalities
included: a characteristic high-stepping pelvic limb gait (pseudo-
hypermetria of the hock), inability to bear weight, and stumbling.
Gait abnormalities were required to be fairly symmetrical. Some
degree of atrophy of the pelvic musculature may also have been
exhibited. Accepted laryngeal abnormalities included: a change in
the bark quality (tone, pitch, etc.), respiratory stridor, difficulty
breathing and/or swallowing, laryngeal paresis or laryngeal
paralysis (as observed by endoscopic examination) and laryngeal
tieback surgery. Other diseases that may mimic any of these signs,
such as neoplasias, paraneoplastic syndromes, hypothyroidism,
diabetes mellitus, etc., were ruled out to the extent possible.
Thirty-six cases met these qualifications. Of the remaining sixteen
cases used in the GWAS, a subset (n = 8) met the above
qualifications, but only exhibited either a gait abnormality or a
laryngeal abnormality, but not both. Another subset (n = 2) did not
have a nerve biopsy available, but had undergone nerve
conduction velocity (NCV) testing, revealing abnormal (decreased
or absent) NCVs. These dogs also had a gait abnormality and a
laryngeal abnormality. A final subset (n = 6) had both a gait
abnormality and a laryngeal abnormality, but no nerve biopsy and
no NCV testing.
These 52 cases included ten of the cases described previously
[9]. Twenty-nine (24 male, 5 female) of the cases developed
clinical signs of polyneuropathy before or at three years of age,
while the other 23 (16 male, 7 female) cases developed signs at an
age older than three years. Forty of the 52 cases (77%) were male
and 12 of the cases (23%) were female.
Controls (n= 41). The dog must have been at least eight
years of age at the time it was genotyped or at the time of death,
with no laryngeal abnormalities and no gait abnormalities (as
described above) reported. For 14 of the controls, post-mortem
peripheral nerve biopsies were processed and examined at UCSD
or by another veterinary neurohistopathologist, using proper
plastic embedding techniques, and showed no evidence of nerve
fiber loss beyond that which is normal for age-related changes. A
subset (n = 4) of the controls had all of the above criteria, but were
seven years old at the time genotyped or at the time of death. A
final subset (n = 23) were over the age of eight and were clear of all
clinical signs, but had not been biopsied post-mortem.
Phenotype Classification of Additional Leonberger Dogs
Validation group. To better assess the relationships between
genotype and phenotype, as well as sex and age-of-onset of clinical
signs, and in order to validate the association between the
ARHGEF10 deletion and PN-affected status, we examined an
independent set of Leonberger samples (n = 314). Control dogs
(n = 160) were restricted to those aged eight years or older with no
laryngeal or gait abnormalities. Cases (n = 154) included possible
PN clinical signs, and: either having a nerve biopsy with
pathological changes consistent with PN (n= 60 of 154), abnormal
NCV test results (n = 2 of 154), a diagnosis for laryngeal paralysis
(with or without tieback surgery) and a gait abnormality (n = 43 of
154), or having a gait and breathing abnormality together (n = 49
of 154). Medical information was provided by the owners and
veterinarians as above.
Global group. To estimate the allele frequencies in a world-
wide population of Leonbergers, we utilized the combined sample
set that has been received by UM and UB in response to
availability of an LPN1 genotyping test (n = 4,074). This represents
a sample pool originating primarily from the North American and
European continents, as well as Australia/New Zealand. Very few
samples have been tested which originated from Asia and South
America. The dogs used in the GWAS and the validation group
above are pooled in this global total.
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DNA and RNA Extraction
Genomic DNAwas isolated from blood or tissue using the Gentra
PureGene blood kit (Qiagen, Germantown, USA) according to
standard protocols; for tissue, the modified protocol for DNA
purification from paraffin-embedded tissues from the same kit was
used. Total RNA was isolated using TRIzol (Life Technologies,
Grand Island, NY, USA), according to manufacturer’s instructions.
Genome-Wide Association Mapping and Haplotype
Analysis
Initially, genomic DNA from 52 cases and 41 controls was
genotyped on the Illumina CanineHD BeadChip (Illumina, San
Diego, CA, USA) that contains 173,662 SNP markers. SNP
genotype data was analyzed in PLINK [11], and subjected to
standard quality control, where SNPs were excluded for poor
genotyping rates (,90%), low minor allele frequencies (,0.05), or
deviation from Hardy Weinberg equilibrium in controls (p,
0.001), and dogs were excluded for low genotyping success (,
90%). The data were subjected to chi-square tests of association,
and 10,000 phenotype label-swapping permutations were utilized
to determine genome-wide significance. Population stratification,
resulting from close familial relationships, was confirmed by the
genomic inflation factor calculated during the chi-square associ-
ation test. Therefore, we applied a mixed model approach utilizing
the GenABEL package [12], with 100,000 permutations, to
correct for this population stratification and any cryptic related-
ness. Haplotypes around significantly associated loci were
constructed using PHASE [34,35]. All bp positions used are
reported from the May 2005 (Broad/CanFam2) build of the
canine genome, in order to be synchronized with the SNP arrays.
Mutation Analysis of Canine ARHGEF10
Primers for the amplification of the coding region of
ARHGEF10 were designed with the software Primer 3 after
masking repetitive sequences with RepeatMasker. We amplified
PCR products (conditions available upon request) using MJ
Research PTC-100 thermal cyclers (MJ Research, Inc., Water-
town, MA, USA) covering exons and flanking intronic regions
using AmpliTaqGold360Mastermix (Life Technologies, Grand
Island, NY, USA). Re-sequencing of the PCR products was
performed after rAPid alkaline phosphatase (Roche Diagnostics
Corporation, Indianapolis, IN, USA) and exonuclease I (New
England Biolabs (NEB), Ipswich, MA, USA) treatment using both
PCR primers with the ABI BigDye Terminator Sequencing Kit
3.1 (Life Technologies, Grand Island, NY, USA) on an ABI 3730
genetic analyzer. We analyzed the sequence data with Sequencher
5.1 (GeneCodes, Ann Arbor, MI, USA).
We used two assays to genotype additional dogs. In the first
assay, the following primers were used in PCR (conditions
available upon request) to produce either a 380 or 390 bp length
product: AGCCACTTTCGGGATTCTTC (F) and TGTTC-
CCTTGGTCACAGGAC (R). PCR products were then digested
with 3 U ApaLI enzyme (NEB, Ipswich, MA, USA) at 37uC for
three hours with standard NEB reaction conditions. Digested
products were visualized on 2% agarose gel: fragments with the
deletion are 354 bp in length and fragments without the deletion
are 307 bp in length. In the second assay, fragment size analyses
was performed for the genotyping of the ARHGEF10 deletion
(primers: CGGGTCTTCATGCTCAGTG (F) and TGTTCC-
CTTGGTCACAGGAC (R)) on an ABI 3730 capillary sequencer
and analyzed with the GeneMapper 4.0 software (Life Technol-
ogies, Grand Island, NY, USA).
The deletion was further confirmed in cDNA prepared from
tissue with RT-PCR. Total RNA was isolated under RNase-free
conditions from flash frozen brain (Cavalier King Charles Spaniel,
a control dog), spinal cord (Leonberger, an ARHGEF10 D/N dog
with no polyneuropathy), and peripheral nerve tissue (Leonberger,
one PN affected dog with ARHGEF10 D/D genotype) using
Trizol’s (Life Technologies, Grand Island, NY, USA) manufac-
turer instructions. Total RNA was reverse transcribed into cDNA
using the Super Script II kit (Life Technologies, Grand Island, NY,
USA), following the manufacturer’s standard protocol. cDNA was
then subjected to PCR and sequenced using intron-spanning
primers (GCGGTCCGACGATATGATAG – F, ACACCTG-
CTTTCTCCAGCAC – R) located in exon 17 and 19.
Throughout the manuscript, all ARHGEF10 cDNA numbering
refers to accession XM_846774.3 and all protein numbering refers
to accession XP_851867.3.
Additional Genotyping of a CFA7 Locus
An RFLP assay specific to a SNP (TIGRP2P93473_rs9189862)
tagging the originally significantly associated CFA7 haplotype was
developed in order to genotype a larger population. The following
primers were used in PCR (conditions available upon request) to
produce a 290 bp product: AGATTCCCAATCCCTGCTTC (F)
and AGGCAGGGCTATTCTTTTGG (R). PCR products were
then digested with 5 U HaeIII enzyme (NEB, Ipswich, MA, USA)
at 37uC for three hours with standard NEB reaction conditions
and visualized on 2% agarose gels.
Web Resources
Inherited Peripheral Neuropathies Mutation Database (URL:
http://www.molgen.ua.ac.be/cmtmutations/home/IPN.cfm)
University of California, Santa Cruz Genome Browser (URL:
www.genome.ucsc.edu)
American Kennel Club Leonberger Breed History (URL:
http://www.akc.org/breeds/leonberger/history.cfm)
Primer 3 (URL: http://frodo.wi.mit.edu/primer3/)
RepeatMasker (URL: http://repeatmasker.genome.washington.
edu)
Supporting Information
Supporting Information S1 LPN1 genetic test result interpre-
tation and breeding recommendations.
(PDF)
Table S1 All observed Polymorphisms in ARHGEF10 sequenc-
ing in case and control Leonbergers.
(XLSX)
Table S2 Number of dogs screened for ARHGEF10 deletion.
(XLSX)
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